![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
MRTX1133 is an investigational, highly potent, selective and reversible inhibitor of KRASG12D that is optimized to sustain near complete target inhibition. It is currently being investigated for KRASG12D-driven cancers.
Lead Product(s): MRTX1133
Therapeutic Area: Oncology Product Name: MRTX1133
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023